RVNC Quote, Financials, Valuation and Earnings

Ligand Pharmaceuticals has a net margin of -63.65% compared to Revance Therapeutics's net margin of -13.84%. Revance Therapeutics's return on equity of -- beat Ligand Pharmaceuticals's return on equity of 5.97%.

Revance Therapeutics has a consensus price target of $7.64, signalling upside risk potential of 148.77%. On the other hand Ligand Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 26.54%. Given that Revance Therapeutics has higher upside potential than Ligand Pharmaceuticals, analysts believe Revance Therapeutics is more attractive than Ligand Pharmaceuticals.

Revance Therapeutics has a beta of 0.815, which suggesting that the stock is 18.478% less volatile than S&P 500. In comparison Ligand Pharmaceuticals has a beta of 1.038, suggesting its more volatile than the S&P 500 by 3.81%.

Revance Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revance Therapeutics pays -- of its earnings as a dividend. Ligand Pharmaceuticals pays out -- of its earnings as a dividend.

Revance Therapeutics quarterly revenues are $59.9M, which are larger than Ligand Pharmaceuticals quarterly revenues of $51.8M. Revance Therapeutics's net income of -$38.1M is lower than Ligand Pharmaceuticals's net income of -$7.2M. Notably, Revance Therapeutics's price-to-earnings ratio is -- while Ligand Pharmaceuticals's PE ratio is 45.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revance Therapeutics is 1.16x versus 13.48x for Ligand Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

MEI Pharma has a net margin of -63.65% compared to Revance Therapeutics's net margin of --. Revance Therapeutics's return on equity of -- beat MEI Pharma's return on equity of --.

Revance Therapeutics has a consensus price target of $7.64, signalling upside risk potential of 148.77%. On the other hand MEI Pharma has an analysts' consensus of -- which suggests that it could grow by 747.46%. Given that MEI Pharma has higher upside potential than Revance Therapeutics, analysts believe MEI Pharma is more attractive than Revance Therapeutics.

Revance Therapeutics has a beta of 0.815, which suggesting that the stock is 18.478% less volatile than S&P 500. In comparison MEI Pharma has a beta of 0.790, suggesting its less volatile than the S&P 500 by 21.017%.

Revance Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MEI Pharma offers a yield of 0% to investors and pays a quarterly dividend of $1.75 per share. Revance Therapeutics pays -- of its earnings as a dividend. MEI Pharma pays out 65.59% of its earnings as a dividend. MEI Pharma's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revance Therapeutics quarterly revenues are $59.9M, which are larger than MEI Pharma quarterly revenues of --. Revance Therapeutics's net income of -$38.1M is lower than MEI Pharma's net income of -$8M. Notably, Revance Therapeutics's price-to-earnings ratio is -- while MEI Pharma's PE ratio is 1.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revance Therapeutics is 1.16x versus 0.15x for MEI Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -63.65% compared to Revance Therapeutics's net margin of 36.03%. Revance Therapeutics's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Revance Therapeutics has a consensus price target of $7.64, signalling upside risk potential of 148.77%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.26%. Given that Revance Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Revance Therapeutics is more attractive than Regeneron Pharmaceuticals.

Revance Therapeutics has a beta of 0.815, which suggesting that the stock is 18.478% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Revance Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revance Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Revance Therapeutics quarterly revenues are $59.9M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Revance Therapeutics's net income of -$38.1M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Revance Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revance Therapeutics is 1.16x versus 5.94x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals has a net margin of -63.65% compared to Revance Therapeutics's net margin of -367.46%. Revance Therapeutics's return on equity of -- beat Recursion Pharmaceuticals's return on equity of -78.32%.

Revance Therapeutics has a consensus price target of $7.64, signalling upside risk potential of 148.77%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 41.02%. Given that Revance Therapeutics has higher upside potential than Recursion Pharmaceuticals, analysts believe Revance Therapeutics is more attractive than Recursion Pharmaceuticals.

Revance Therapeutics has a beta of 0.815, which suggesting that the stock is 18.478% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Revance Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revance Therapeutics pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

Revance Therapeutics quarterly revenues are $59.9M, which are larger than Recursion Pharmaceuticals quarterly revenues of $26.1M. Revance Therapeutics's net income of -$38.1M is higher than Recursion Pharmaceuticals's net income of -$95.8M. Notably, Revance Therapeutics's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revance Therapeutics is 1.16x versus 26.59x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.